Organon & Co.
OGN US68622V1061
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Cox Carrie Smith |
8.07 USD |
12,469 Bought |
100,591 USD |
14/05/2025 | 14/05/2025 |
Cox Carrie Smith |
8.07 USD |
12,469 Bought |
100,591 USD |
14/05/2025 | 14/05/2025 |
Falcione Aaron HR H |
8.77 USD |
5,500 Bought |
48,235 USD |
07/05/2025 | 07/05/2025 |
Falcione Aaron HR H |
8.77 USD |
5,500 Bought |
48,235 USD |
07/05/2025 | 07/05/2025 |
Weaver Kirke SEC |
9.21 USD |
8,045 Bought |
74,054 USD |
06/05/2025 | 06/05/2025 |
Karp Daniel EX VP |
8.24 USD |
3,500 Bought |
28,828 USD |
06/05/2025 | 06/05/2025 |
Karp Daniel EX VP |
8.24 USD |
3,500 Bought |
28,828 USD |
06/05/2025 | 06/05/2025 |
Walsh Matthew M CFO |
8.82 USD |
11,400 Bought |
100,548 USD |
05/05/2025 | 05/05/2025 |
Ali Kevin CEO |
8.81 USD |
34,000 Bought |
299,370 USD |
05/05/2025 | 05/05/2025 |
Ali Kevin CEO |
8.81 USD |
34,000 Bought |
299,370 USD |
05/05/2025 | 05/05/2025 |